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Abstract
Jacobsen syndrome is a MCA/MR contiguous gene syndrome caused by partial deletion of the long
arm of chromosome 11. To date, over 200 cases have been reported. The prevalence has been
estimated at 1/100,000 births, with a female/male ratio 2:1. The most common clinical features
include pre- and postnatal physical growth retardation, psychomotor retardation, and
characteristic facial dysmorphism (skull deformities, hypertelorism, ptosis, coloboma, downslanting
palpebral fissures, epicanthal folds, broad nasal bridge, short nose, v-shaped mouth, small ears, low
set posteriorly rotated ears). Abnormal platelet function, thrombocytopenia or pancytopenia are
usually present at birth. Patients commonly have malformations of the heart, kidney,
gastrointestinal tract, genitalia, central nervous system and skeleton. Ocular, hearing,
immunological and hormonal problems may be also present. The deletion size ranges from ~7 to
20 Mb, with the proximal breakpoint within or telomeric to subband 11q23.3 and the deletion
extending usually to the telomere. The deletion is de novo in 85% of reported cases, and in 15% of
cases it results from an unbalanced segregation of a familial balanced translocation or from other
chromosome rearrangements. In a minority of cases the breakpoint is at the FRA11B fragile site.
Diagnosis is based on clinical findings (intellectual deficit, facial dysmorphic features and
thrombocytopenia) and confirmed by cytogenetics analysis. Differential diagnoses include Turner
and Noonan syndromes, and acquired thrombocytopenia due to sepsis. Prenatal diagnosis of 11q
deletion is possible by amniocentesis or chorionic villus sampling and cytogenetic analysis.
Management is multi-disciplinary and requires evaluation by general pediatrician, pediatric
cardiologist, neurologist, ophthalmologist. Auditory tests, blood tests, endocrine and
immunological assessment and follow-up should be offered to all patients. Cardiac malformations
can be very severe and require heart surgery in the neonatal period. Newborns with Jacobsen
syndrome may have difficulties in feeding and tube feeding may be necessary. Special attention
should be devoted due to hematological problems. About 20% of children die during the first two
years of life, most commonly related to complications from congenital heart disease, and less
commonly from bleeding. For patients who survive the neonatal period and infancy, the life
expectancy remains unknown.
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Disease name and synonyms
Jacobsen Syndrome; JBS
Monosomy 11qter
Partial deletion 11q
Distal deletion 11q
Distal monosomy 11q
Telomeric deletion 11q
11q-syndrome
Del 11q ter
Del 11q23.3
Definition
Jacobsen syndrome (JS) is a contiguous gene syndrome
caused by partial deletion of the long arm of chromosome
11. The condition was first described by Jacobsen in 1973
in a family with multiple members that inherited an
unbalanced 11;21 translocation derived from a balanced
translocation carrier parent [1]. The deletion size ranges
from 7 to 20 Mb [2,3]. The breakpoints occur within or
distal to subband 11q23.3 and the deletion usually
extends to the telomere. Larger terminal deletions extend-
ing proximal to 11q23.3 probably result in embryonic
lethality, and in some old reports of such deletions the
breakpoint might have been misinterpreted due to techni-
cal limits of banding resolution [4]. A large terminal dele-
tion with break occurring at band 11q21 has been
reported, in the mosaic form, in a patient with a severe
complex phenotype with holoprosencephaly and cyclopia
[5]. A partial JS phenotype is observed in three patients
from a kindred with a very small pure terminal deletions
[6]. Partial phenotype is also observed in interstitial dele-
tions rarely occurring within the JS region [7,8].
More commonly, interstitial deletions occur in 11q cen-
tromeric to the JS region, giving a distinct clinical pheno-
type.
The most common clinical features of JS include: pre- and
postnatal physical growth retardation, psychomotor retar-
dation, characteristic facial dysmorphism, thrombocyto-
penia or pancytopenia. A subset of patients have
malformations of the heart, kidney, gastrointestinal tract,
genitalia, central nervous system and/or skeleton. Ocular,
hearing, immunological and hormonal problems may be
also present [2,3].
Although patients with the largest deletions usually show
more severe clinical manifestations and cognitive impair-
ment, some of the phenotype demonstrate incomplete
penetrance and are highly variable between patients.
Epidemiology
More than 200 cases of JS have been so far reported in the
literature [3,9]. The estimated occurrence of JS is about 1/
100,000 births [2,3,9]. The female/male ratio is 2:1.
Clinical description
Data on clinical findings are based on a thorough review
of the literature concerning over 200 published cases and
personal experience with 62 children with pure 11q termi-
nal deletions (some of whom are also included in above
mentioned literature reports) that we have assessed
directly. Patients with JS are born at term in more than
60% cases, premature birth occurs in about 30% of cases,
while delivery is post term in less than 10% of cases. Com-
plications at delivery occur in 46% of cases: abnormal
fetal presentation, premature rupture of the membranes,
cephalopelvic disproportion. Delivery is spontaneous in
about 65% of cases, whereas Cesarean section is per-
formed in 35% of cases. Birth weight is normal (between
the 10th and the 90th percentile) in 60% of babies, below
the 10th percentile in 37%, while 3% of children have a
birth weight above the 90th percentile. Mean maternal age
is 27 years, mean paternal age is 30 years. During the neo-
natal period, most JS children have prolonged hospitali-
zations, due most commonly to a combination of feeding
difficulties, cardiac problems, and/or bleeding problems.
About 20% of children die during the first two years of
life, most commonly related to complications from con-
genital heart disease, and less commonly from bleeding.
For patients who survive the neonatal period and infancy,
the life expectancy is unknown, Dr. Jacobsen's index case
is 45 years old and is living in a group home.
There is a wide spectrum of severity of the clinical pheno-
type. Half of the patients are diagnosed by age one year of
life, usually those with the more obvious clinical features
of the disorder, while children with milder features may
be diagnosed at an older age.
Physical growth delay
Height is below the 10th percentile in 75% of cases and in
the normal range in 25%. Weight is below the 10th percen-
tile in 58%, normal in 34% and above the 90th percentile
in 8% of cases. Head circumference is below the 10th per-
centile in 26%, normal in 53% and above the 90th percen-
tile in 21% of cases.
Psychomotor developmental delay
Mental development is normal or borderline in less than
3% of cases, mild to severe mental retardation is observed
in 97% of cases. The degree of neurocognitive deficiency
is strongly associated with the size of the deletion [3,10].Orphanet Journal of Rare Diseases 2009, 4:9 http://www.ojrd.com/content/4/1/9
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Children manifest behavioral problems, most frequently
attention deficit/hyperactivity disorder, while more severe
psychiatric disorders such as schizophrenia, or bipolar
affective disorder have been reported rarely [11,12]. Sei-
zures have been reported infrequently.
Dysmorphic features and minor malformations
Typical features are: skull deformities (macrocrania, high
prominent forehead, facial asymmetry, trigonocephaly),
ocular hypertelorism, downslanting palpebral fissures,
strabismus, palpebral ptosis, sparse eyebrows, epicanthal
folds, eyelid coloboma, ectropion, iris coloboma, cataract,
tortuosity of retinal vessels, flat or prominent nasal
bridge, short nose, anteverted nares, prominent colume-
lla, broad nasal bridge, small ears, low set posteriorly
rotated ears, malformed external ears, hypoplastic lobus,
long philtrum, flat philtrum, v-shaped mouth, thin upper
lip, retrognathia, and other less frequently observed (Fig-
ure 1). Hands show cutaneous syndactyly, flat finger pads
with fetal tubercule, thin fingers, large 1st interphalangeal
joints, hypoplastic hypotenar regions, abnormal palmar
creases, hypoplastic thenar regions. Feet are stubby and
flat, with large and long first toe, clynodactylous toes,
brachydactyly, syndactyly of the 2nd and 3rd toes, crowded
toes. The main features of JS, based on 35 patients that we
have assessed, are listed in Table 1. In some reports the
presence of trigonocephaly has been described as a com-
mon feature. Trigonocephaly is an abnormality of the
Table 1: Features in Jacobsen syndrome
Very frequent (> 40%) Less frequent (< 40%)
Craniofacial abnormalities Skull deformities, macrocrania
High prominent forehead
Facial asymmetry
Trigonocephaly (see Text)
Eyes Ocular hypertelorism
Downslanting palpebral fissures
Divergent or convergent strabismus
Palpebral ptosis
Sparse eyebrows
Epicanthal folds
Eyelid coloboma
Ectropion
Iris coloboma
Cataract
Tortuosity of retinal vessels
Nose Flat nasal bridge (early aspect)
Prominent nasal bridge (late aspect)
Short nose
Anteverted nares
Prominent columella
Broad nasal bridge
Ears Small ears
Low set ears
Posteriorly rotated ears
Malformed external ears
Hypoplastic lobus
Mouth Long philtrum
Flat philtrum
V-shape mouth
Thin upper lip
Retrognathia
High arched palate
Thick lower lip
Dental anomalies
Neck Short neck Webbed neck
Hands Cutaneous syndactyly
Flat finger pads with fetal tubercule
Thin fingers, large 1st interphalangeal joints
Hypoplastic hypotenar regions
Abnormal palmar creases
Hypoplastic tenar
Feet Stubby and flat feet
Large and long first toe
Clynodactylous toes
Brachydactyly
Syndactyly of II and III toes
Crowded toes
Zygodactyly (toes 2 and 3 very similar)Orphanet Journal of Rare Diseases 2009, 4:9 http://www.ojrd.com/content/4/1/9
Page 4 of 10
(page number not for citation purposes)
skull shape characterized by a triangular appearance of the
forehead when the head is viewed from above. It is often
associated with premature closure of the metopic suture.
The presence of trigonocephaly gives the patient a very
characteristic facial appearance that raises the possibility
of the diagnosis, however in our experience the frequency
of trigonocephaly in JS patients seems less high than pre-
viously reported (< 30%). The prevalence of trigonoceph-
aly at birth is reported as 67:1,000,000 in the general
population; in a series of 25 children selected for the pres-
ence of syndromic and non syndromic trigonocephaly,
two out of seven syndromic cases (28.5%) were JS patients
[13].
Visceral malformations
Congenital heart malformations occur in 56% of cases.
Most of these require medications and/or surgical repair.
Cardiac malformations were reported in 95% of deceased
children [14]. The most frequent heart defects (2/3 of
patients that have congenital heart defects) are ventricular
septal defects, or left heart obstructive malformations:
abnormalities of aortic or mitral valves, coartation of the
aorta, Shone's complex, or hypoplastic left heart syn-
drome. Hypoplastic left heart syndrome, a rare and severe
condition that occurs in about 1/5000 infants, is observed
in 5% of JS children. The other one third of patients with
heart defects have a wide spectrum of most of the com-
mon heart defects that occur in the general population of
patients with congenital heart disease [3]. Gastrointestinal
tract malformations occur in 18% of reported cases, and
in 25% the patients we have assessed, including pyloric
stenosis, anal abnormalities (atresia or stenosis, or anteri-
orized anus), and less frequently, duodenal atresia, annu-
lar pancreas, or gut malrotation. Functional abnormalities
of the gastrointestinal tract also occur frequently, includ-
ing feeding difficulties in the neonatal period and chronic
constipation, requiring medication, beyond the newborn
period. Among JS patients who were analyzed with cere-
bral ultrasound, computed tomography (CT), or magnetic
resonance imaging (MRI) scanning or by autopsy, 65%
had some kind of structural abnormality of the brain:
enlarged ventricles with or without spina bifida, cerebral
atrophy, agenesis of corpus callosum, pachygiria [15].
Supratentorial abnormalities of the white matter are inter-
preted as due to delay of myelinization [14,16,17], or par-
tial loss of astrocytes, rather than a process of
demyelinization [9].
Urinary system malformations are observed in 13% of JS
children: unilateral kidney dysplasia, double urethers,
double kidney district, hydronephrosis, multicystic kid-
neys. Cryptorchidism is observed in 36% of males in pub-
lished reports, and in about 60% our series. Inguinal
hernias are observed in 15% of children.
In addition to craniosynostosis, 14% of children display
some skeletal abnormality including spina bifida occulta,
vertebral body anomalies, chest anomalies, abnormal
number of ribs, micromelia, hexadactyly. Orthopedics
abnormalities are observed in 19% of children including
hip dislocation, scoliosis, flat feet, or clubbed feet.
Hematological, hormonal and immunological aspects
Most patients with the JS are born with either thrombocy-
topenia or pancytopenia. More recently a definite platelet
disorder, the Paris-Trousseau syndrome, has been
reported in patients with JS [18,19]. This platelet abnor-
mality is highly penetrant in JS, affecting at least 88.5% of
cases, and it has been suggested that the platelet abnor-
mality in JS and the Paris-Trousseau syndrome are the
same condition [19,20]: Paris-Trousseau syndrome is
characterized by neonatal thrombocytopenia which may
resolve over time, and platelet dysfunction (which is usu-
ally persistent). In peripheral blood there are two different
types of abnormal platelets: giant platelets and platelets
with giant alpha granules. Platelets showing giant alpha
granules are a minority, but their amount is variable in
different patients and in the same patient at different
times. Immunocytochemical and ultrastructural studies
demonstrated that the giant granules arise by abnormal
fusion of smaller organelles [19]. These abnormally fused
alpha granules may be due to a failure of the alpha gran-
ules to release their contents that are required for coagula-
tion, under normal physiologic conditions. In the bone
marrow there is an increased number of small megakary-
ocytes (micromegakaryocytes), and delayed maturation
of megakaryocytes [21]. It has been observed that in JS the
platelets have a reduced number of serotonin adenine rich
dense bodies, suggesting a storage pool deficit [22].
Growth hormone (IGF-1) and thyroid-stimulating hor-
mone (TSH) deficiency have been reported in patients
with JS [9,23].
Although JS infants show recurrent otitis and sinusitis,
deficit of cellular or humoral immunity with low IgM and
Facial dysmophism in Jacobsen syndrome patients Figure 1
Facial dysmophism in Jacobsen syndrome patients.Orphanet Journal of Rare Diseases 2009, 4:9 http://www.ojrd.com/content/4/1/9
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IgA has been reported only occasionally [24,25]. Cutane-
ous eczema is observed in 22% of JS children, but there is
no obvious increased risk for severe allergic reaction to
food or medications [3].
Malignancies
Somatic acquired chromosome deletions of 11q overlap-
ping the JS region have been demonstrated in a variety of
malignancies of adulthood, frequently associated with
aggressive progression of the disease and poor prognosis. It
might be expected, therefore, that constitutional deletions
of 11q regions result in an increased risk for developing
neoplastic lesions and/or poor prognosis. There is no evi-
dence of increased risk of malignancies in JS patients from
the literature, but clinical reports have concerned mainly JS
children, and little is known about their outcome in older
ages. Better clinical management of JS children leading to
longer survivals could reveal an increased risk for the devel-
opment of malignancies in JS patients in adulthood. Alter-
natively, it is possible that deletion of 11q terminal region
is causally related only with an aggressive progression of
cancer rather than with an increased risk of neoplastic
transformation and cancer onset [3,26].
Etiology
In JS the chromosome aberration is usually a de novo pure
terminal deletion (85% of cases). Less frequently, unbal-
anced translocations result from segregation of a familial
balanced translocation, as in the original report by Jacob-
sen [1]. Alternatively, partial deletion of chromosome 11q
may result from unbalanced translocations occurring de
novo, or from other chromosomal rearrangements such as
ring chromosomes [2,27] or recombination of a parental
pericentric inversion. In these cases 11q deletion is com-
plicated by additional imbalances.
Chromosome 11q deletion has also been reported in the
mosaic form [5,25,28,29].
In a subset of patients the breakpoints cluster in 11q23.3,
close to a rare folate sensitive fragile site FRA11B [2,29].
Folate sensitive fragile sites are caused by the extensive
expansion of (CGG)n repeats and hypermethylation of
adjacent CpG islands. The FRA11B  site A is a (CGG)n
repeat in the 5' untranslated region (UTR) of the CBL2 pro-
tooncogene [30,31], which maps to between 118, 575, 702
and 118,775,922 bp. [32] (Figure 2). In more than 70% of
normal individuals this repeat is present in 11 copies, while
in individuals with cytogenetic expression of the FRA11B
the repeat is expanded to several hundred copies. The CCG
repeats can expand to 80–100 copies as a premutation,
without cytogenetic expression of the fragile site.
Jones et al. reported that in two JS patients the expansion
of the CCG repeat at the FRA11B, with or without cytoge-
netic expression of the fragile site, was at the origin of the
11qter deletion. In both cases the deleted chromosome
was maternal [30,31]. It is hypothesized that hypermeth-
ylation of the expanded (CCG)n triplets on chromosome
11 could delay DNA replication of this fragile site, result-
ing in a break and/or impaired DNA replication [33].
Only a minority of cases of JS (10%) are related to ampli-
fication of the CCG triplet at the FRA11B folate sensitive
fragile site, and individuals with the FRA11B rarely have
children with JS. Therefore, the presence of the FRA11B
fragile site may increase the risk of having JS offspring, but
not necessarily result in a child with an 11q deletion. Most
11q deletions occur distally to the FRA11B, and it is pos-
sible that expansion at other fragile sites may be responsi-
ble for distal 11q deletions [33,34]. However, to date no
other fragile sites have been identified in the parents of JS
patients with deletions whose breakpoints map telomeric
to the FRA11B fragile site [3].
Alternatively, smaller deletions are likely to occur by other
mechanisms: it has been shown that chromosome recom-
binations can be mediated by low copy repeats (LCR),
palindromic AT-rich repeats (PATRRs), olfactory receptor
gene clusters (ORGC) [35-37]. Taken together, there are
likely to be multiple mechanisms that lead to the genera-
tion of 11q deletions.
In JS patients the origin of the deleted chromosome is
more likely to be maternal for breakpoints occurring prox-
imally to D11S924 (band 11q23.3), while there is a pater-
nal bias when the breakpoint is more distal. It is likely that
imprinting is involved in the mechanisms of (CCG)n
expansion and methylation [2,31].
Genotype/phenotype correlation
Although the patients with the largest deletions usually
show the most severe phenotype, this can vary between
patients. For example, as described above, almost all
patients have Paris-Trousseau syndrome, but only 56% of
patients have a congenital heart defect, independent of
the size of their deletion. The minimal region for express-
ing the JS phenotype spans about 14 Mb [38,39].
Features of JS, resulting in a partial expression of the JS
phenotype, have been observed in patients with very
small terminal deletions and in cases of interstitial dele-
tions spanning within the JS region [6-8].
A terminal deletion of about 5 Mb, with a breakpoint at
129.5 Mb, was reported in three patients from a kindred,
with some facial features of JS, with or without mental
retardation, and without cardiac malformation and
thrombocytopenia [6].
Some facial features of JS, heart defect and the Paris-Trous-
seau thrombocytopenia, have been observed in a childOrphanet Journal of Rare Diseases 2009, 4:9 http://www.ojrd.com/content/4/1/9
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with an interstitial deletion of about 10 Mb spanning
between 120.0/121.5 and 129.7/130.6, thus almost
entirely proximal to that of previous report [7].
Two further patients with interstitial deletions have been
reported to show some features of JS, but not the distinct
and recognizable facial aspect [8]. The region spanning
between 120 and 130.6 Mb is probably the most impor-
tant for the expression of the phenotype.
Attempts to correlate the clinical findings to the extent of
the deletion, complicated by incomplete penetrance for
specific phenotypes as described above, has nonetheless
provided the following results: Trigonocephaly and skin
syndactyly have been localized to a region defined
between D11S933 (124 Mb) and D11S912 (128 Mb)
[2,32]. Phillips et al. (2002) refined the critical region for
hypoplastic left heart and trigonocephaly to a region dis-
tal to D11S1351 [40], mapping to 127.5–127.7 Mb,
according to UCSC database [32]. Grossfeld [3] mapped
the Paris-Trousseau platelet disorder, cryptorchidism,
pyloric stenosis, and mental retardation to the 6.8 Mb tel-
omeric region spanning from D11S1351 (127.5 Mb) [32].
The region spanning from D11S707 (125.7 Mb) to the tel-
omere is associated with cardiac defects [3], but more than
one gene might be involved in cardiac malformation
[7,8]. The region distal to D11S1299 (119 Mb) [32] is
related to ocular coloboma [3]. Genotype – phenotype
correlation has been attempted also in reports concerning
patients where 11q terminal deletions are due to the seg-
regation of unbalanced translocations [41-43]. These
cases may allow further refinement of the phenotype
mapping, however a possible role of the associated dupli-
cations must be considered.
Relevant genes and loci
11q23 qter is a gene rich region: it includes 342 genes, 174
of which have been localized to 11q24.1 qter, the minimal
region for expressing the JS, of about 14 Mb [35]. The FLI-
1 gene maps to chromosome subband 11q24, in the region
deleted in JS patients. It is a proto-oncogene belonging to
the  ETS  family and interacting with a number of genes
involved in vasculogenesis, hematopoiesis and intercellular
adhesion. There is in vivo and in vitro evidence that FLI1
plays a fundamental role in megakaryocytes differentiation
and that heterozygous loss of the FLI-1 gene is associated
with dysmegakaryocytopoiesis and the Paris-Tousseau
trombocytopenia in JS [19,44]. Furthermore, in vitro
induced over-expression of the FLI-1 gene in patient (i.e.
patients that are haplo-insufficient for FLI-1) CD34+ cells,
restores normal megakaryopoiesis [45], however other
genes in distal 11q may also contribute to this disorder. The
BARX 2 gene maps to chromosome 11q, within the mini-
mal deleted region for JS. It has four exons and encodes a
homeobox protein. Its murine homologue barx2  is
expressed in the development of neural and craniofacial
11q23.3-qter Figure 2
11q23.3-qter. From left to right: ideogram, megabase posi-
tion (Mb), most relevant genes, markers. The position of 
genes and markers is from UCSC the human march 2006 
assembly [32].Orphanet Journal of Rare Diseases 2009, 4:9 http://www.ojrd.com/content/4/1/9
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structures [46]. The BARX 2 gene, because of its location
and its expression pattern, is a possible candidate gene for
the development of facial dysmorphism and/or craniosyn-
ostosis in JS [46]. However no mutation in the BARX2 gene
has been detected in nine patients with isolated trigono-
cephaly [46]. JAM3 has been considered a candidate gene
for hypoplastic left heart and trigonocephaly. It is a mem-
ber of the junction adhesion molecules family; the gene
maps within the critical region for hypoplastic left heart
(HLH) that is a 9 Mb region in the long arm of chromo-
some 11 distal to D11S1351 (127.5 Mb). Analysis of the
JAM3 gene in thirty-three patients with isolated HLH, failed
to demonstrate any mutation; this would suggest that other
genes are mainly involved in this malformation [7]. Tyson
et al. [8], suggested that a critical region for the conotruncal
heart defect may lie within a region spanning between
129.03 and 130.6 Mb, which bears ADAMTS8, a gene
involved in angiogenesis.
B3GAT1, a beta-1–3-glycoronyltransferase gene located in
11q25 at 133.77 Mb, is expressed in the brain. Knock out
mice show impaired synaptic plasticity and learning disa-
bilities [47]. This gene could be involved in bipolar disor-
der observed in some JS patients [12].BSX, an
evolutionarily highly conserved homeobox gene,
expressed during early brain development and mapping
in 122.3 Mb has been proposed as a candidate gene for
global cognitive development, while NRGN  (neuro-
granin), a gene involved in synapse plasticity and long-
term potentiation and mapping in 124.1 Mb has been
suggested to contribute to the auditory attention deficit
[10]. Abnormalities of the white matter appear to map
between 124.6 Mb, and 129.03 and hypothetical candi-
date genes include FEZ1, involved in axonal outgrowth,
and RICS, highly expressed in developing brain [8].
KCNJ1, a potassium channel, and ADAMTS15, a zinc-
dependent proteases expressed in fetal liver and kidney
may be related to kidney malformations [8].
TECTA, a gene coding for a non collagenous component
of the tectorial membrane of the inner ear, may be
involved in neurosensorial deafness [48].
A number of tumor related genes map in 11q distal
region: EST1, CHK1, BARX2, OPCML, FLI-1, their role in
tumor development and progression in JS is still
unknown (Figure 2).
Diagnosis
In patients with the classical phenotype the diagnosis is
suspected on the basis of clinical findings: mental retarda-
tion, facial dysmorphic features and thrombocytopenia.
The diagnosis must be confirmed by cytogenetic analysis.
The clinical diagnosis may be difficult in patients with less
characteristic clinical aspects and borderline mental devel-
opment; in these cases the observation of thrombocytope-
nia or pancytopenia may suggest the diagnosis. Children
with fewer manifestations of JS may be less likely to be
diagnosed early, based on clinical phenotype.
Differential diagnosis
Children with JS share some clinical features (short stat-
ure, short, wide, sometimes webbed neck, downslanting
palpebral fissures, ptosis, aortic or pulmonary stenosis)
with Turner and Noonan syndromes. In Noonan syn-
drome patients, common features with JS patient are also
thrombocytopenia and bleeding tendency. Occasionally,
JS children have had a clinical diagnosis of Kabuki syn-
drome (mental retardation, unusual palpebral fissures,
short stature, fingerpads). Neonatal bleeding and throm-
bocytopenia may be misdiagnosed as acquired thrombo-
cytopenia due to sepsis.
Genetic counseling
In families with a de novo chromosome rearrangement the
recurrence risk is generally considered negligible. How-
ever in de novo terminal deletions 11q, recurrence has
been documented in at least four children from two unre-
lated families [3,49]. Therefore prenatal diagnosis is war-
ranted as the possibility of gonadal mosaicism or any
other predisposing condition in one parent cannot be
excluded. In families with the fragile site FRA11B, the
recurrence risk is non quantifiable but probably slightly
increased, and prenatal diagnosis could be considered.
When a parent is affected with JS [17,18], the recurrence
risk is 50%. There is a high recurrence risk when a parent
has a balanced translocation, or deletion 11q in the
mosaic form.
Antenatal diagnosis
Only a few prenatal cases of 11q terminal deletion have
been reported [50-52]. Prenatal diagnosis of 11q deletion
is possible by amniocentesis or chorionic villus sampling
and cytogenetic analysis with standard G-banding and, if
necessary, telomeric FISH. The test is indicated when there
is a known risk for 11q deletion (familial balanced trans-
location, mosaicism or FRA11B in a parent). The cytoge-
netic test may also be performed when there is an
abnormal prenatal serum screening test for Down syn-
drome or abnormal prenatal ultrasound that may suggest
the occurrence of a chromosome unbalance. In some
cases of deletion 11q, oligohydramnios, nuchal thicken-
ing, heart malformations and kidney duplication have
been observed prenatally.
Management and treatment
After the diagnosis of JS a complete evaluation should be
performed including:
￿ clinical assessment by a general pediatricianOrphanet Journal of Rare Diseases 2009, 4:9 http://www.ojrd.com/content/4/1/9
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￿ baseline evaluation by a pediatric cardiologist, including
EKG and echocardiogram
￿ baseline evaluation by a neurologist, including baseline,
and potentially serial brain imaging studies
￿ abdominal ultrasound scan to exclude pyloric stenosis,
and kidney and urinary tract malformations.
￿ ophthalmologic examination, including dilation of the
pupils
￿ auditory tests
￿ blood tests: blood cells counts, platelets counts, platelets
function studies, bleeding time
￿ endocrine: IGF1 and TSH
￿ immunological assessment: IgM, IgA, IgG.
In the neonatal period children with JS frequently require
special assistance and treatment. Cardiac malformations
can be very severe and require heart surgery in the neonatal
period. JS children may have difficulties in feeding and tube
feeding may be necessary. Special attention should be
devoted due to hematological problems. Due to thrombo-
cytopenia and abnormal platelet function, bleeding is most
likely to occur in infancy. Platelet count can eventually
reach low normal values, but functional abnormalities usu-
ally persist. In some patients pancytopenia is observed. Pro-
phylactic platelets or whole blood transfusion may be
necessary before, as well as during or after surgery. Bone
marrow biopsy is usually not necessary. Early craniotomy is
indicated in children with craniosynostosis.
At the follow up
pediatric evaluation, serial blood tests including platelets
counts, cardiac evaluation (for the development of pro-
gressive lesions such as aortic or mitral valve stenosis),
ophthalmologic and auditory tests should be performed,
and can be individualized to each patient's needs. During
the first years of life children have an increased risk of
recurrent infections. Thyroid hormone deficiency should
be treated accordingly. Most JS patients have short stature,
half of whom have growth hormone (IGF-1) deficiency.
Treatment with growth hormone replacement therapy is
controversial, since these patients may have a genetic pre-
disposition to certain malignancies that could be exacer-
bated by a tumor promoter. Eye surgery may be necessary
to correct strabismus, as untreated strabismus may result
in amblyopia. It is critical that surgery be performed in the
first year of life to prevent this complication.
Severe ptosis must be corrected to allow walking; however
abnormal external eye muscles may cause relapse of ptosis or
strabismus after surgery. Treatment of orthopedic problems
should be individualized. Early intervention with occupa-
tion, speech, physical and behavioral therapists is critical to
address cognitive and behavioral problems. Recently, music
therapy has been shown to be beneficial to some of these
patients (manuscript in preparation). JS children can be vac-
cinated according to the standard schedule [3].
Surgery
As described above, children with JS frequently require
surgical treatment interventions. Thrombocytopenia and
other hematological problems must be taken into account
preoperatively. Prophylactic transfusion with platelets can
be lifesaving. Due to abnormalities of the pharynx main-
taining the airway and intubation might be difficult [53].
Prognosis
A proportion of children with JS die in the neonatal
period, usually due to severe heart malformations and
bleeding. Many patients that survive the neonatal period
will require long-term care including surgical and medical
interventions. Life expectancy is unknown. The oldest
known living patient with JS is 45 years old. There is
apparently no known increased risk of malignancies.
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